445 results on '"Stoppa, A.-M."'
Search Results
2. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
3. Qualidade de vida de pacientes acometidos por COVID-19
4. A Christian Integrative Perspective on Nurturing Civic Development among Emerging Adults
5. Defining a Moment in History: Parent Communication with Adolescents about September 11, 2001
6. Social justice development among emerging adult students: The influence of families, peers, and religious congregations
7. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
8. Longitudinal Changes in Religiosity among Emerging Adult College Students
9. Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission
10. Positive Sexual Communication and Socialization in the Parent-Adolescent Context
11. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
12. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP) : Updated Results of a Randomized Study
13. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
14. Experiences of Parents of Adult Survivors’ Disclosures of Child Sexual Abuse
15. Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma
16. Phase I–II Study of Carboplatin with VP16 and Aracytin for Poor-Risk-Acute Leukemia
17. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity
18. IL2 in Acute Leukemia
19. Phase I-II trial of Seraspenide (AcSDKP): a supressor of myelopoiesis protects against chemotherapy myelotoxicity (version 10 february 1993)
20. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
21. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
22. Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia
23. Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study
24. Treatment of Relapsed Acute Leukemias with Systemic Recombinant Interleukin 2 (RU 49637)
25. Tolerance and Biological Activity of Bolus Administration of Increasing Doses of Glycosylated Recombinant Interleukin-2 (SR 29009) in Patients with Hematological Malignancy
26. Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies
27. Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience
28. Minor clone provides a reservoir for relapse in multiple myeloma
29. The Roles of Religiousness and Spirituality in the Sexual Lives of Heterosexual Emerging Adults
30. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs
31. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT
32. Automated washing of autologous hematopoietic stem cell grafts after thawing does not impair engraftment
33. T CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR REFRACTORY MULTIPLE MYELOMA USING NONMYELOABLATIVE CONDITIONING AND HIGH-DOSE POST TRANSPLANT CYCLOPHOSPHAMIDE: PH-P526
34. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
35. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation
36. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma
37. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
38. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
39. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
40. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience
41. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
42. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
43. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
44. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
45. Autologous peripheral blood stem cell transplantation (PBSCT) in acute myeloid leukaemia (AML) in first complete remission (CR) a report of the BGMT cooperative group about 32 patients
46. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
47. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients
48. Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involment
49. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial
50. Allogeneic haematopoietic stem cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Comparative analysis of outcomes between unrelated and related donor: P1126
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.